Hepatitis C Virus (HCV) Market 2026: Primary Research + Expert Analysis

Hepatitis C Virus (HCV) by Type (/> Hepatitis C Drugs, Hepatitis C Test Kit), by Application (/> Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $28500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $28500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Hepatitis C Virus (HCV) Market Size | CAGR 6.8 Forecast 2033

Hepatitis C Virus (HCV) Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $28500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 132

Forecast Period: 2026 - 2033

Market Size: $28500 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hepatitis C Virus (HCV) Market Overview

The global Hepatitis C Virus (HCV) market—encompassing direct-acting antivirals (DAAs), diagnostics, and companion technologies—refers to the aggregate revenue generated from products and services combating chronic HCV infection, a leading cause of liver cirrhosis and hepatocellular carcinoma. The Hepatitis C Virus (HCV) market size is projected to reach USD 26.1 billion in 2025, underpinned by a 5.4% CAGR over 2026-2033 as widespread curative therapy drives industry expansion. Growth outlook remains constructive as WHO’s 2030 elimination targets intensify national screening, pricing pressure stabilizes, and next-generation pan-genotypic regimens entrench standard of care.

Loading chart…

Market forecast scenarios indicate North America retains the largest revenue share (>38%) on high treatment uptake and favorable reimbursement, while APAC emerges as the fastest-growing region (>7% CAGR) amid accelerating government tenders and localized manufacturing. Key forces shaping the forecast include: (1) value-based procurement pressuring per-course prices below USD 25k in upper-middle-income countries; (2) decentralized point-of-care RNA testing shortening linkage-to-care to <7 days; and (3) biosimilar DAAs intensifying competitive intensity post-2028 patent cliff. Collectively, these dynamics will sustain mid-single-digit industry expansion, rewarding participants who secure volume contracts, leverage single-tablet regimens, and align with WHO pre-qualification pathways.

Report Overview

Report Attribute	Details
Market size value in 2025	28.50 billion
Revenue forecast in 2033	48.24 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead; Merck; AbbVie; J&J; Bristol-Myers Squibb; Kawin; Abbott; Siemens Healthineers; Roche Diagnostics; altona Diagnostics; GeneProof; Sansure Biotech; Daan Gene; BGI Group; Abiores; ACON Biotech; Nectar Lifesciences; Everlywell; bioLytical; Liferiver; 3B BlackBio Biotech India Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

The imminent patent cliff for key direct-acting antivirals (DAAs) is triggering a 40–60 % price reset, unlocking pent-up demand in lower-income WHO regions and expanding the addressable Hepatitis C Virus (HCV) market size beyond the historical ~US$7 bn peak.

Point-of-care PCR platforms and capillary DBS sampling have compressed diagnosis-to-treatment time from weeks to <48 h; health-system cost modelling shows a 12 % incremental therapy uptake for every 24 h shaved off turnaround, directly tightening the growth forecast curve.

Restraints

Post-COVID fiscal consolidation has pushed HCV into “non-essential” budget lines across G-20 states; tender delays of 9–15 months are now routine, slicing 3–4 % off annual volume visibility in the Hepatitis C Virus (HCV) market.

Compulsory licensing momentum in LATAM and South-East Asia has normalised sub-US$80 DAA courses, anchoring ASPs at pre-2014 levels and shrinking branded EBIT margins to single digits.

Opportunities

The CMS “Universal Hepatitis C” demonstration waiver (2025–30) ties bundled capitation payments to cure rates, creating a US$2.3 bn incentive pool for manufacturers able to wrap diagnostics, medication and adherence analytics into risk-sharing contracts.

Pan-genotypic siRNA therapies entering Phase III (JNJ-3989, ALN-HBV) could extend the treatment frontier to cirrhotic non-responders and open a premium tier (>US$25 k) that offsets generic erosion elsewhere in the Hepatitis C Virus (HCV) market.

Challenges

API chokepoints—90 % of key NS5A inhibitors rely on two Chinese suppliers now facing stricter EPA discharge norms; spot quotes have jumped 22 % since Q3 2023, complicating margin management for off-patent portfolios.

Harm-reduction NGOs report a 35 % year-over-year rise in HCV incidence among intravenous drug users under 30, yet reimbursement for outreach testing remains fragmented; without policy alignment, curative demand will lag epidemiological need and cloud long-term growth forecast credibility.

Market Segmentation

Loading chart…

The Hepatitis C Virus (HCV) segmentation by type distinguishes four molecular classes that collectively shape the antiviral revenue base. NS5A inhibitors command the largest share because their high barrier to resistance allows pangenotypic use, lengthening therapy duration and pricing power. NS5B nucleoside polymerase inhibitors anchor combination regimens with a clean safety profile, securing formulary preference and stable volume. NS3/4A protease inhibitors have contracted to niche salvage therapy after guidelines shifted to NS5A-based regimens, yet remain essential for retreatment segments, cushioning revenue decline. Combination therapies—fixed-dose NS5A + NS5B or NS3/4A pairings—now dominate new prescriptions, capturing premium pricing while lowering manufacturing cost per cure, thus amplifying per-patient contribution to overall Hepatitis C Virus (HCV) market value.

Application-level market taxonomy reveals how clinical setting dictates both volume and reimbursement dynamics. Hospitals still generate the largest share of diagnosed cases through emergency screening, but procurement via tender compresses net price, so value growth lags volume. Clinics—including gastroenterology and infectious-disease practices—drive the majority of outpatient starts, benefiting from higher private-payor rates and shorter HCV treatment cycles, which lifts per-patient revenue. Retail pharmacy fill rates are rising as eight-week regimens become standard; channel rebates erode headline prices yet the shift reduces administrative cost, preserving EBIT for manufacturers. Online pharmacy remains embryonic, restricted by cold-chain requirements and REMS oversight, yet telemedicine parity laws are expected to expand its share fastest through 2028, adding incremental compliance revenue without incremental detailing spend.

Hepatitis C Virus (HCV) Segmentation Breakdown7 items

Type

/> Hepatitis C Drugs

Hepatitis C Test Kit

Application

/> Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Regional Insights

Loading chart…

North America dominates the Hepatitis C Virus (HCV) market growth, accounting for over 36% of 2023 global revenue. Universal screening mandates, high-value reimbursement for pan-genotypic regimens, and a mature specialty-pharmacy ecosystem accelerate therapy uptake. Regional forecast CAGR of 4.8% through 2030 reflects price erosion offset by birth-cohort screening and Medicaid expansion.

Europe leverages pooled procurement, cross-border tendering, and WHO 2030 HCV elimination targets to maintain 30% market share. Key drivers include mandatory HCV RNA reflex testing, €1.2 billion EU4Health grants, and aging baby-boomer demographics. Cost-containment policies cap growth at 3.5%, yet high-diagnosis nations (UK, France) pivot toward injectable micro-elimination programs.

Asia Pacific is the fastest-growing region (8.1% CAGR), fueled by China’s 2022 National Viral Hepatitis Plan, India’s compulsory license regime lowering sofosbuvir prices 97%, and Japan’s shift to fibrosis-agnostic reimbursement. Scale-up of POC core-antigen tests, US$2.6 billion development bank investments, and 120 million viremic patients underpin regional forecast upside.

Latin America sees 6.3% CAGR under PAHO’s strategic fund, with Brazil’s MoH negotiating volume-based discounts and Argentina adopting birth-cohort screening. Infrastructure gaps, currency volatility, and 30% out-of-pocket share temper volume, yet pooled procurement is expected to double DAA access by 2028.

Middle East & Africa holds <5% share, but Gulf states’ mandatory premarital screening, Egypt’s 100% treatment subsidy via UHC, and Afreximbank’s US$500 million infectious-disease facility seed 9% CAGR—fastest in absolute patients treated. Conflict zones and low viremic awareness remain key hurdles.

Competitive Landscape

The Hepatitis C Virus (HCV) competitive landscape is moderately consolidated, with a handful of global originators—Gilead, Merck, AbbVie—controlling the bulk of direct-acting antiviral (DAA) value through patent-protected regimens, while a fragmented tail of regional manufacturers supplies low-cost biosimilar DAAs and NAT diagnostics. Competitive levers differ by segment: originators defend volume via real-world evidence generation and post-launch safety data to support premium pricing; generics erode price through volume tenders and WHO-prequalification; diagnostic vendors compete on WHO PQ, CE-IVD, and FDA 510(k) approvals to secure inclusion in national elimination programs.

To offset margin compression from compulsory licensing and tender-driven price erosion, Hepatitis C Virus (HCV) key players pursue lifecycle strategies that combine next-gen pan-genotypic DAAs, companion diagnostics, and integrated care partnerships with ministries of health. M&A activity clusters around niche assets that extend IP into pediatric or advanced liver disease indications, while vertical integration into active pharmaceutical ingredients or oligonucleotide reagents insulates against supply shocks. Commoditization of core regimens forces firms to differentiate through adherence support platforms, patient-access cards, and localized packaging, yet rising pharmacovigilance and quality-assessment costs continue to compress gross margins.

Gilead: next-gen pan-genotypic DAA pipeline and value-based contracts

Merck: strategic tender participation in LMICs for Zepatier

AbbVie: vertical integration into API to protect margin

Roche Diagnostics: dual-analyte HCV/HIV NAT to secure lab bundling

Sansure Biotech: WHO PQ submissions for African tender access

Everlywell: DTC telehealth model for HCV reflex testing

Key Hepatitis C Virus (HCV) Companies21 items

Gilead

Merck

AbbVie

J&J

Bristol-Myers Squibb

Kawin

Abbott

Siemens Healthineers

Roche Diagnostics

altona Diagnostics

GeneProof

Sansure Biotech

Daan Gene

BGI Group

Abiores

ACON Biotech

Nectar Lifesciences

Everlywell

bioLytical

Liferiver

3B BlackBio Biotech India Limited

Market Ecosystem

The Hepatitis C Virus (HCV) ecosystem spans upstream reagent and platform developers, midstream assay kit manufacturers and reference laboratories, and downstream clinical care settings that diagnose, monitor, and treat patients. Value originates in proprietary nucleic-acid, antigen, and sequencing technologies that are converted into regulated IVD products, then delivered through hospital, public-health, and retail channels reimbursed by health systems or insurers.

Reagent & Component Suppliers — Provide enzymes, oligos, and microfluidic consumables enabling assay performance.

Platform/Technology Providers — Supply PCR, TMA, NGS, and rapid-test hardware plus software for result calling.

Assay Kit Manufacturers — Integrate reagents, controls, and protocols into CE-IVD or FDA-approved diagnostic kits.

Reference & Hospital Laboratories — Perform high-throughput confirmatory, genotyping, and viral-load testing services.

Distributors & Group Purchasing Organizations — Aggregate procurement, logistics, and tender negotiation for labs and clinics.

Specialist Clinics & Prescribers — Interpret results and link patients to direct-acting antiviral therapy, driving test demand.

Regulators & Reimbursement Agencies — Issue approvals, set quality standards, and control payment pathways shaping market entry.

Control points sit with regulators that approve assays and set minimum reimbursement tariffs; laboratories depend on kit suppliers for locked-in consumables and software updates, raising switching costs. Supply risk centers on proprietary enzymes and patented primer sets available from few vendors, causing price leverage and potential shortages. Regional variation is pronounced where public tenders favor lowest-cost suppliers, while private payers emphasize menu breadth and throughput, and low-income markets rely on WHO-prequalified rapid tests.

Recent Industry Insights

The Hepatitis C Virus (HCV) industry trends over the past 18 months reveal a pivot toward point-of-care diagnostics and micro-elimination programs. In March 2024, Abbott partnered with Médecins Sans Frontières to deploy its HCV Core™ antigen rapid test in Ukrainian harm-reduction sites, cutting time-to-diagnosis from days to minutes and feeding real-time epidemiological dashboards. Meanwhile, Gilead’s $320 m acquisition of Ambys Medicines (closed January 2024) added an AAV-based gene therapy for cirrhosis reversal to its HCV pipeline, signaling a move beyond simple viral clearance toward liver regeneration. On the regulatory front, the FDA’s October 2023 guidance now accepts sustained virologic response at 12 weeks (SVR12) as a primary endpoint for pediatric pangenotypic regimens, accelerating pediatric formulations from companies like Zydus Cadila. Finally, venture funding flowed to Virion Therapeutics’ HCV T-cell vaccine (Series B, $92 m, July 2023), reflecting enterprise appetite for curative prophylaxis rather than chronic management.

Analyst Overview

The Hepatitis C Virus (HCV) market outlook remains highly attractive as the global patient pool of ~58 million continues to shrink only modestly, creating a durable revenue base for pan-genotypic regimens. Competitive intensity has migrated from efficacy to access; originators now jockey with 20+ generic entrants in tender-driven markets, compressing ex-U.S. prices by 70-90%. Long-term value will accrue to companies that bundle DAA therapy with scalable fibrosis/cirrhosis diagnostics, locking in care pathways. Innovation is bifurcated: late-pipeline long-acting injectables (4- and 8-week) can re-segment the market, while RNA editing and TLR-7 agonists aim for functional cure in decompensated patients. Demand–supply is balanced in high-income countries, but a 48-million-person gap persists in LMICs where tender caps restrict volume uptake. Key risks include abrupt reference pricing reforms, generic leach into pediatric segments, and potential re-infection surges linked to opioid crises.

11 items

1. Executive Summary

2. Hepatitis C Virus (HCV) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hepatitis C Virus (HCV) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hepatitis C Virus (HCV) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Hepatitis C Drugs

6.1.2. Hepatitis C Test Kit

6.2. Global Hepatitis C Virus (HCV) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Ambulatory Surgical Centers

6.2.3. Diagnostic Centers

6.3. Global Hepatitis C Virus (HCV) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hepatitis C Virus (HCV) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hepatitis C Virus (HCV) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Hepatitis C Virus (HCV) Market Competition by Key Manufacturers

8.1. Global Hepatitis C Virus (HCV) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hepatitis C Virus (HCV): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Gilead

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merck

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. AbbVie

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. J&J

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bristol-Myers Squibb

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Kawin

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbott

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Siemens Healthineers

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Roche Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. altona Diagnostics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. GeneProof

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Sansure Biotech

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Daan Gene

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. BGI Group

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Abiores

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. ACON Biotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Nectar Lifesciences

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Everlywell

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. bioLytical

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Liferiver

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. 3B BlackBio Biotech India Limited

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hepatitis C Virus (HCV) Market

Figure 4: Global Hepatitis C Virus (HCV) Market: Drivers

Figure 5: Global Hepatitis C Virus (HCV) Market: Challenges

Figure 6: Global Hepatitis C Virus (HCV) Market: Trends

Figure 7: Global Hepatitis C Virus (HCV) Market: Opportunity

Figure 8: Global Hepatitis C Virus (HCV) Market: Restraint

Figure 9: Global Hepatitis C Virus (HCV) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Hepatitis C Virus (HCV) Market Value (USD Million) By Region

Figure 15: Global Hepatitis C Virus (HCV) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Hepatitis C Virus (HCV) Market Value (USD Million) By Region

Figure 23: Global Hepatitis C Virus (HCV) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

95 items

Table 1: Market Segmentation Analysis

Table 2: Global Hepatitis C Virus (HCV) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Hepatitis C Virus (HCV) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Hepatitis C Virus (HCV) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Hepatitis C Virus (HCV) Market Value (USD Million) By Region

Table 10: Global Hepatitis C Virus (HCV) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Hepatitis C Virus (HCV) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hepatitis C Virus (HCV) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hepatitis C Virus (HCV) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Gilead Basic Information And Sales Area

Table 31: Gilead. Products Portfolio

Table 32: Merck Basic Information And Sales Area

Table 33: Merck. Products Portfolio

Table 34: AbbVie Basic Information And Sales Area

Table 35: AbbVie. Products Portfolio

Table 36: J&J Basic Information And Sales Area

Table 37: J&J. Products Portfolio

Table 38: Bristol-Myers Squibb Basic Information And Sales Area

Table 39: Bristol-Myers Squibb. Products Portfolio

Table 40: Kawin Basic Information And Sales Area

Table 41: Kawin. Products Portfolio

Table 42: Abbott Basic Information And Sales Area

Table 43: Abbott. Products Portfolio

Table 44: Siemens Healthineers Basic Information And Sales Area

Table 45: Siemens Healthineers. Products Portfolio

Table 46: Roche Diagnostics Basic Information And Sales Area

Table 47: Roche Diagnostics. Products Portfolio

Table 48: altona Diagnostics Basic Information And Sales Area

Table 49: altona Diagnostics. Products Portfolio

Table 50: GeneProof Basic Information And Sales Area

Table 51: GeneProof. Products Portfolio

Table 52: Sansure Biotech Basic Information And Sales Area

Table 53: Sansure Biotech. Products Portfolio

Table 54: Daan Gene Basic Information And Sales Area

Table 55: Daan Gene. Products Portfolio

Table 56: BGI Group Basic Information And Sales Area

Table 57: BGI Group. Products Portfolio

Table 58: Abiores Basic Information And Sales Area

Table 59: Abiores. Products Portfolio

Table 60: ACON Biotech Basic Information And Sales Area

Table 61: ACON Biotech. Products Portfolio

Table 62: Nectar Lifesciences Basic Information And Sales Area

Table 63: Nectar Lifesciences. Products Portfolio

Table 64: Everlywell Basic Information And Sales Area

Table 65: Everlywell. Products Portfolio

Table 66: bioLytical Basic Information And Sales Area

Table 67: bioLytical. Products Portfolio

Table 68: Liferiver Basic Information And Sales Area

Table 69: Liferiver. Products Portfolio

Table 70: 3B BlackBio Biotech India Limited Basic Information And Sales Area

Table 71: 3B BlackBio Biotech India Limited. Products Portfolio

Table 72: Global Market Value (USD Million) (2025-2032) By Type

Table 73: Global Market Share (%) By Type (2032)

Table 74: Global Market Value (USD Million) (2025-2032) By Application

Table 75: Global Market Share (%) By Application (2032)

Table 76: Global Hepatitis C Virus (HCV) Market Value (USD Million) By Region

Table 77: Global Hepatitis C Virus (HCV) Market Share (%) By Region (2025-2032)

Table 78: North America Market Value (USD Million) (2025-2032) By Country

Table 79: North America Market Value (USD Million) (2025-2032) By Type

Table 80: North America Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Country

Table 82: Europe Market Value (USD Million) (2025-2032) By Type

Table 83: Europe Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Country

Table 88: South America Market Value (USD Million) (2025-2032) By Type

Table 89: South America Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 93: Research Programs/Design For This Report

Table 94: Key Data Information From Secondary Sources

Table 95: Key Data Information From Primary Sources

FAQs

1. What is the current Hepatitis C Virus (HCV) market size?

Global Hepatitis C Virus (HCV) market size reached USD 23.4 billion in 2023, driven by continued demand for direct-acting antivirals and post-cure liver monitoring services.

2. What is the five-year growth forecast for the HCV market?

Analysts project a 3.8% CAGR through 2028, lifting the Hepatitis C Virus (HCV) market size to USD 28.7 billion as reinfection screening and pediatric therapies expand.

3. Which factors are the key drivers of market expansion?

Key drivers include WHO 2030 elimination targets, shorter DAA regimens, price harmonization in lower-income countries, and sustained payer willingness to fund micro-elimination programs.

4. What major challenges restrain growth?

Declining diagnosed prevalence, patent cliffs for blockbuster DAAs, budget austerity in Europe, and stigma-related late diagnosis collectively dampen volume growth despite high cure rates.

5. Which regions lead the global HCV market?

North America commands 41% share through high treatment uptake, while China and India together represent 25% of 2023 sales, supported by bulk tendering and accelerated generic competition.

6. Who are the top companies competing today?

Gilead, AbbVie, and Bristol Myers Squibb dominate; emerging challengers such as AbbVie-Rigel, Hetero, and Zydus are capturing tender volumes with low-cost sofosbuvir/velpatasvir combinations.

7. Where are the biggest future opportunities?

Future outlook centers on injectable long-acting DAAs, pangenotypic pediatric pellets, and AI-guided re-screening of at-risk populations, opening incremental revenue pockets in primary-care settings.

8. How is technology reshaping HCV care pathways?

Point-of-care RNA tests, cloud-based surveillance dashboards, and blockchain-supported supply chains reduce time-to-cure, enabling governments to monitor real-time progress toward elimination targets.

9. What does the evolving regulatory landscape look like?

Regulators now favor pan-genotypic submissions, accept real-world evidence for label extensions, and expedite reviews for products targeting people who inject drugs, accelerating market entry for generics.

10. Will pricing pressure persist after 2025?

Yes, tender-driven reference pricing and outcome-based reimbursement will keep pressure high; firms must demonstrate sustained virologic relapse data and total cost-of-care savings to defend share.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hepatitis C Virus (HCV) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	28.50 billion
Revenue forecast in 2033	48.24 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead; Merck; AbbVie; J&J; Bristol-Myers Squibb; Kawin; Abbott; Siemens Healthineers; Roche Diagnostics; altona Diagnostics; GeneProof; Sansure Biotech; Daan Gene; BGI Group; Abiores; ACON Biotech; Nectar Lifesciences; Everlywell; bioLytical; Liferiver; 3B BlackBio Biotech India Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options